MA55560A - Dérivés d'amide n-hétéroaromatiques destinés au traitement du cancer - Google Patents

Dérivés d'amide n-hétéroaromatiques destinés au traitement du cancer

Info

Publication number
MA55560A
MA55560A MA055560A MA55560A MA55560A MA 55560 A MA55560 A MA 55560A MA 055560 A MA055560 A MA 055560A MA 55560 A MA55560 A MA 55560A MA 55560 A MA55560 A MA 55560A
Authority
MA
Morocco
Prior art keywords
cancer
treatment
amide derivatives
heteroaromatic amide
heteroaromatic
Prior art date
Application number
MA055560A
Other languages
English (en)
Inventor
Liming Bao
Chaole Chen
John J Talley
Liangliang Xu
Xuan Yang
Chaochun Zhang
Chenggang Zhu
Original Assignee
Shenzhen Forward Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shenzhen Forward Pharmaceuticals Co Ltd filed Critical Shenzhen Forward Pharmaceuticals Co Ltd
Publication of MA55560A publication Critical patent/MA55560A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
    • C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MA055560A 2019-03-29 2020-03-30 Dérivés d'amide n-hétéroaromatiques destinés au traitement du cancer MA55560A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201910252714 2019-03-29
CN201910616031 2019-07-09

Publications (1)

Publication Number Publication Date
MA55560A true MA55560A (fr) 2022-02-09

Family

ID=72664733

Family Applications (1)

Application Number Title Priority Date Filing Date
MA055560A MA55560A (fr) 2019-03-29 2020-03-30 Dérivés d'amide n-hétéroaromatiques destinés au traitement du cancer

Country Status (8)

Country Link
US (1) US20220177473A1 (fr)
EP (1) EP3950686A4 (fr)
JP (1) JP7337951B2 (fr)
KR (1) KR20210144853A (fr)
CN (3) CN111747931A (fr)
AU (1) AU2020255100C1 (fr)
MA (1) MA55560A (fr)
WO (1) WO2020200158A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021104305A1 (fr) * 2019-11-26 2021-06-03 上海翰森生物医药科技有限公司 Inhibiteur d'un dérivé polycyclique contenant de l'azote, son procédé de préparation et son utilisation
WO2021259315A1 (fr) * 2020-06-23 2021-12-30 深圳福沃药业有限公司 Sel de composé et composition pharmaceutique le contenant
WO2022033455A1 (fr) * 2020-08-13 2022-02-17 上海和誉生物医药科技有限公司 Dérivé de triazine ayant une activité inhibitrice d'egfr, son procédé de préparation et son utilisation
KR20240027583A (ko) * 2021-04-30 2024-03-04 수조우 푸허 바이오파마 컴퍼니 리미티드 폐암 치료를 위한 피리미디닐아미노벤젠
WO2022237825A1 (fr) * 2021-05-13 2022-11-17 上海和誉生物医药科技有限公司 Dérivé d'azaaryle ayant une activité inhibitrice de l'egfr, son procédé de préparation et son utilisation
US20240299387A1 (en) * 2021-06-22 2024-09-12 Blueprint Medicines Corporation Heterocyclic egfr inhibitors for use in the treatment of cancer
WO2022271612A1 (fr) * 2021-06-22 2022-12-29 Blueprint Medicines Corporation Inhibiteurs hétérocycliques d'egfr destinés à être utilisés dans le traitement du cancer
WO2022271630A1 (fr) * 2021-06-22 2022-12-29 Blueprint Medicines Corporation Inhibiteurs de l'egfr
WO2022271613A1 (fr) * 2021-06-22 2022-12-29 Blueprint Medicines Corporation Inhibiteurs hétérocycliques d'egfr destinés à être utilisés dans le traitement du cancer
CN113387935B (zh) * 2021-07-23 2022-06-10 苏州雅深智慧科技有限公司 抑制三突变表皮生长因子受体酪氨酸激酶的化合物及用途
WO2024094064A1 (fr) * 2022-11-02 2024-05-10 Suzhou Puhe Biopharma Co., Ltd Pyrimidinylaminobenzènes pour le traitement du cancer du poumon avec métastase distante

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0216786B1 (fr) * 1984-12-21 1992-03-18 Biogen, Inc. Purification, production et utilisation de facteurs necrotiques tumoraux
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
PL194689B1 (pl) 1996-02-13 2007-06-29 Astrazeneca Uk Ltd Pochodne chinazoliny, ich kompozycje farmaceutyczne oraz ich zastosowania
NZ331191A (en) 1996-03-05 2000-03-27 Zeneca Ltd 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
PL205557B1 (pl) 1999-02-10 2010-05-31 Astrazeneca Ab Pochodne indolu
NZ522074A (en) 2000-05-31 2004-06-25 Astrazeneca Ab Indole derivatives with vascular damaging activity
IL153325A0 (en) 2000-07-07 2003-07-06 Angiogene Pharm Ltd Colchinol derivatives as angiogenesis inhibitors
MXPA02012905A (es) 2000-07-07 2004-07-30 Angiogene Pharm Ltd Derivados de colquinol como agentes de dano vascular..
WO2010129053A2 (fr) * 2009-05-05 2010-11-11 Dana Farber Cancer Institute Inhibiteurs d'egfr et procédés de traitement de troubles
HUE032515T2 (en) * 2010-06-23 2017-09-28 Hanmi Science Co Ltd New condensed pyrimidine derivatives for inhibiting tyrosine kinase activity
SI2736895T1 (sl) * 2011-07-27 2016-03-31 Astrazeneca Ab Derivati 2-(2,4,5-substituiranega-anilino) pirimidina, kot modulatorji EGFR uporabni za zdravljenje raka
JO3300B1 (ar) * 2012-06-06 2018-09-16 Novartis Ag مركبات وتركيبات لتعديل نشاط egfr
MX361992B (es) * 2012-08-06 2018-12-19 Acea Biosciences Inc Compuestos de pirrolopirimidina novedosos como inhibidores de proteínas quinasas.
HUE034568T2 (en) * 2013-03-06 2018-02-28 Astrazeneca Ab Quinazoline inhibitors for inhibiting the activation of mutant forms of epidermal growth factor receptors
CN104860941B (zh) * 2014-02-25 2017-03-22 上海海雁医药科技有限公司 2,4‑二取代苯‑1,5‑二胺衍生物及其应用以及由其制备的药物组合物和药用组合物
KR102663309B1 (ko) * 2014-03-20 2024-05-03 카펠라 테라퓨틱스, 인크. 암 치료용의 ｅｒｂｂ 티로신 키나제 억제제로서의 벤즈이미다졸 유도체
WO2015188747A1 (fr) * 2014-06-12 2015-12-17 南京圣和药业股份有限公司 Composé de triazine substitué par phényle servant d'inhibiteur de l'egfr et ses applications
CN111892579B (zh) * 2014-06-12 2023-07-25 上海艾力斯医药科技股份有限公司 一类激酶抑制剂
MA40240B1 (fr) * 2014-06-19 2019-03-29 Ariad Pharma Inc Composés hétéroaryle d'inhibition de la kinase
CN105254615B (zh) * 2014-07-11 2017-02-22 杭州华东医药集团新药研究院有限公司 苯胺嘧啶衍生物及其在制备抗恶性肿瘤药物中的用途
CN105315259B (zh) * 2014-07-29 2018-03-09 上海艾力斯医药科技有限公司 吡啶胺基嘧啶衍生物、其制备方法及应用
CN105461695B (zh) * 2014-09-29 2018-03-27 齐鲁制药有限公司 嘧啶或三嗪衍生物及其制备方法和用途
ES2886887T3 (es) * 2014-10-11 2021-12-21 Shanghai Hansoh Biomedical Co Ltd Inhibidor de EGFR y preparación y aplicación del mismo
EP4421069A1 (fr) * 2014-10-13 2024-08-28 Yuhan Corporation Composés et compositions pour moduler les activités de kinase mutante egfr
US10266517B2 (en) * 2014-12-23 2019-04-23 Dana-Farber Cancer Institute, Inc. Pyrimidines as EGFR inhibitors and methods of treating disorders
CN106117185B (zh) * 2015-08-31 2017-11-07 广州必贝特医药技术有限公司 2,4‑二含氮基团取代嘧啶类化合物及其制备方法和应用
CN106132957B (zh) * 2015-08-31 2018-06-12 无锡双良生物科技有限公司 2-芳胺基吡啶、嘧啶或三嗪衍生物及其制备方法和用途
RU2606949C9 (ru) * 2015-11-19 2018-03-14 ЗАО "Р-Фарм" Замещенные N-{ 3-[4-(1-метил-1Н-индол-3-ил)пиримидин-2-иламино]-4-метоксифенил} -амиды в качестве модуляторов EGFR, предназначенные для лечения рака
CN106749193B (zh) * 2015-11-23 2020-11-20 南京圣和药业股份有限公司 吲唑取代的表皮生长因子受体抑制剂及其应用
CN106928200A (zh) * 2015-12-30 2017-07-07 湖南福沃药业有限公司 用于治疗癌症的三嗪衍生物
CN106928150B (zh) * 2015-12-31 2020-07-31 恩瑞生物医药科技（上海）有限公司 丙烯酰胺苯胺衍生物及其药学上的应用
CN107163026B (zh) * 2016-03-07 2019-07-02 上海艾力斯医药科技有限公司 吡啶胺基嘧啶衍生物的盐及其制备方法和应用
CN106279160B (zh) * 2016-03-18 2017-09-26 海南越康生物医药有限公司 N‑苯基‑2‑氨基嘧啶类化合物制备方法和用途
CA3016092A1 (fr) * 2016-03-22 2017-09-28 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Forme polycristalline de base libre ou de sel d'acide d'inhibiteur d'egfr, procede pour sa preparation et application
EP3492462B1 (fr) * 2016-07-26 2023-08-30 Shenzhen TargetRx, Inc. Composé amino pyrimidine pour inhiber l'activité de la protéine tyrosine kinase
CN108864079B (zh) * 2017-05-15 2021-04-09 深圳福沃药业有限公司 一种三嗪化合物及其药学上可接受的盐
US20200131176A1 (en) * 2017-07-05 2020-04-30 Cs Pharmatech Limited Selective inhibitors of clinically important mutants of the egfr tyrosine kinase
CN107266437B (zh) * 2017-07-19 2019-08-30 海南越康生物医药有限公司 N-苯基-2-氨基嘧啶类化合物的晶型、盐型及其制备方法
CN108947974B (zh) * 2017-08-30 2020-06-05 深圳市塔吉瑞生物医药有限公司 一种氨基嘧啶类化合物及包含该化合物的组合物及其用途
CN107935995A (zh) * 2017-11-28 2018-04-20 中山大学 一种新型2‑苯胺基嘧啶衍生物及其在制备抗肿瘤药物中的应用
US11266624B2 (en) * 2018-04-03 2022-03-08 Texas Tech University System CRM1 inhibitors reduce primary and acquired resistance of EGFR inhibitors in lung cancer cells
WO2019197605A2 (fr) * 2018-04-12 2019-10-17 Umc Utrecht Holding B.V. Associations médicamenteuses à utiliser dans le traitement du cancer à mutation de ras
WO2020043757A1 (fr) * 2018-08-29 2020-03-05 Universite Nice Sophia Antipolis Prédiction de la réponse au traitement d'une molécule anti-egfr d'un sujet souffrant d'un cancer du rein
CN109761960B (zh) 2019-02-25 2021-08-31 江苏豪森药业集团有限公司 抗耐药抗肿瘤egfr抑制剂的制备方法

Also Published As

Publication number Publication date
AU2020255100A1 (en) 2021-11-25
CN113727982A (zh) 2021-11-30
KR20210144853A (ko) 2021-11-30
EP3950686A1 (fr) 2022-02-09
US20220177473A1 (en) 2022-06-09
WO2020200158A1 (fr) 2020-10-08
CN111747931A (zh) 2020-10-09
CN111747950B (zh) 2024-01-23
JP7337951B2 (ja) 2023-09-04
JP2022529616A (ja) 2022-06-23
CN111747950A (zh) 2020-10-09
AU2020255100C1 (en) 2023-02-23
AU2020255100B2 (en) 2022-11-24
AU2020255100A8 (en) 2021-12-02
EP3950686A4 (fr) 2022-09-07

Similar Documents

Publication Publication Date Title
MA55560A (fr) Dérivés d'amide n-hétéroaromatiques destinés au traitement du cancer
CY1124257T1 (el) N-[4-ΦΘOPO-5-[[(2S,4S)-2-MEΘYΛO-4-[(5-MEΘYΛO-1,2,4-ΟΞAΔIAZOΛ-3-YΛO)MEΘOΞY]-l-ΠΙΠΕΡΙΔΥΛΟ]ΜΕΘΥΛΟ]ΘΕΙΑΖΟΛ-2-ΥΛΟ]ΑΚΕΤΑΜΙΔΙΟ ΩΣ ΑΝΑΣΤΟΛΕΑΣ OGA
DOP2020000037A (es) Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
MA51796A (fr) Procédés et compositions pour l'administration de protéines thérapeutiques
MA55697A (fr) Molécules d'anticorps pour le traitement du cancer
MA51139A (fr) Dérivés de 1-(pipéridinocarbonylméthyl)-2-oxopipérazine pour le traitement du cancer
MA45798A (fr) Compositions et procédés d'inhibition de masp-3 pour le traitement de maladies et troubles divers
MA49141A (fr) Composés pyrrolopyridine-aniline destinés au traitement d'affections de la peau
MA49906A (fr) Acides aminés à chaîne ramifiée pour le traitement d'une maladie du foie
MA50155A (fr) Acides aminés à chaîne ramifiée pour le traitement d'une lésion neuronale
MA52657A (fr) Anticorps spécifiques d'axl pour le traitement du cancer
MA54521A (fr) Dérivés d'oxopyridine substitués
MA56508A (fr) Inhibiteur d'egfr pour le traitement du cancer
IL279397A (en) New compounds and their pharmaceutical preparations for the treatment of diseases
IL290177A (en) History of 4,2,1-oxadiazol-5-one for cancer therapy
MA44864A (fr) Trithérapie pour le traitement d'une maladie intestinale inflammatoire
MA54522A (fr) Composition pharmaceutique pour le traitement de l'hypertension artérielle pulmonaire
MA51613A (fr) Polythérapie pour le traitement ou la prévention du cancer
MA55199A (fr) Leucine, acétyl leucine et analogues apparentés pour le traitement d'une maladie
MA53562A (fr) Polythérapie destinée au traitement d'une maladie hépatique
MA55084A (fr) Administration d'inhibiteurs de pd-1 pour le traitement du cancer de la peau
MA54741A (fr) Composés thiényl-aniline destinés au traitement d'affections de la peau
MA56095A (fr) Méthodes de traitement du cancer à l'aide d'inhibiteurs de prmt5
MA54559A (fr) Polythérapie pour le traitement du cancer
MA55144A (fr) Composés naphthyridinone-aniline destinés au traitement d'affections de la peau